Research within this research group involves research laboratories covering a wide spectrum of interests that include:
fundamental science such as understanding of structure-function basis of novel therapeutic receptors in gene regulatory regions, the development of 2D and 3D cell systems to investigate cellular processes;
applications such as the development of sensors, therapeutics, imaging and targeted delivery systems for anticancer, antimicrobial activity, or bone fracture repair; and
current use such as informing the prescription of therapeutics.
The work is supported by local access to NMR spectroscopy, Mass Spectrometry, fluorescence imaging, single molecule imaging microscopies such as TEM and AFM, cell & tissue culture, animal facilities, chemical synthesis labs, and pharmaceutical formulation facilities among others.
Dr Mamoon Aldeyab and Dr Kathy Burnett work in Pharmacy Practice research, specifically in the (i) identification of antibiotic thresholds and, (ii) health promotion in community pharmacies.
Representative publications: A non-linear time-series analysis approach to identify thresholds in associations between population antibiotic use and rates of resistance. López-Lozano et al. Nature Microbiology (2019).
Professor Ibrahim Banat is interested in the production of biosurfactants for a variety of applications. Biosurfactants have roles in bacterial biofilms disruption on surfaces, have antimicrobial activity with potential roles in food products, wound healing, anticancer, and related applications.
Representative publications: Adjuvant antibiotic activity of acidic sophorolipids with potential for facilitating wound healing. Lydon, et al, Antimicrobial Agents and Chemotherapy. 5, (2017) e02547-16.
Dr Bridgeen Callan, Dr Murtaza Tambuwala, Dr Deborah Lowry, Dr Susan Hawthorne, and Professor Paul McCarron are interested in the development of smart delivery systems, formulation and development of sustained release, and the development of 2D and 3D systems to investigate cellular responses. These applications concern targeted delivery to eye, bone, lungs, and murine models of colitis, but also pancreatic cancer cells, skin cancer, colon cancer cells, and the difficult to work with neuroblastoma cells.
Representative publications: Electroneutral polymersomes for combined cancer chemotherapy. Aibani et al, Acta Biomaterialia, 80(2018)327-340; Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Murphy et al. European Respiratory Journal 49 (2017) 1601731.
Professor John Callan & Prof Tony McHale are interested in the development of minimally invasive processes for targeted therapeutic applications. A significant part of their work involves organic synthesis to create microbubbles loaded with anti-cancer drugs that are administered intravenously, and then ruptured at the target site using ultrasonic energy. Current developments include targeting tumors in pancreatic cancer patients.
Representative publications: A versatile, stimulus-responsive nanoparticle-based platform for use in both sonodynamic and photodynamic cancer therapy. Nomikou et al. Acta Biomaterialia, 49(2017)414-421; Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. McEwan et al., Biomaterials, 80(2016) 20-32.
Dr Mateus Webba da Silva is interested in understanding the structural basis for transcription regulation involving quadruple helix DNA, and the development of nucleic acid functional entities with applications in biomedicine.
Representative publications: Encoding Canonical DNA quadruplex structure. Dvorkin, et al. Science Advances,4, eaat3007 (2018).
Biomedical Science at Ulster University has an outstanding record of success in research, having been awarded the highest possible rating in RAE1996 and 2001, and ranked first place in terms of research power in RAE2008. In REF2014, we were judged to be among the top five universities in terms of research power (out of 92 UK submissions) with 100% four star rating for our research environment.
Biomedical Sciences research activities are currently organized within distinct Research Groups: Diabetes, Food & Health (through Nutrition Innovation Centre for Food and Health (NICHE)), Genomic Medicine, Pharmaceutical Sciences & Practice, Stratified Medicine and Vision Science.
Multi-disciplinary collaboration between the research groups is strongly encouraged and is widespread with research into, for instance, anti-diabetic and antioncogenic aspects of nutrition, the genomics of vitamin receptors, visual deterioration or cancer, imaging of neovascularisation. Our research investigates the interaction between cardiovascular disease and vision and the impact of health and disease, diet, diabetes on dementia, hypertension, vascular and inflammatory disease, to name a few.
In practice, the research groups collaborate both internally and internationally on a range of prioritized multi-disciplinary themes in: ageing, drug discovery and delivery, personalized medicine and genomic medicine. There is also opportunity to undertake research in a number of multi-disciplinary research areas, which combine cutting edge Biomedical Sciences research with psychology, computing and engineering and computational biology. The BMSRI has strong collaborations with regional and global pharmaceutical and diagnostics companies and many of our graduates and postgraduates gain employment in the pharma, diagnostics and health care sectors as well as academia.
The BMSRI offers a "state-of-the-art" research environment for high profile researchers to undertake internationally agenda setting research in strategically prioritized areas of biomedicine. This research environment earned Biomedical Sciences at Ulster a No. 1 ranking in RAE2008, and was again rated as 100% "world-leading" in REF2014. Our research is carried out in well-equipped laboratories allowing the latest methods to be applied to individual projects. Our entire infrastructure is managed as Core Facility Units (CFUs) with equipment and laboratories dedicated to: advanced molecular bioimaging/microscopy, bioinformatics, cell biology, chemical analysis, genomics, proteomics/metabolomics (include Mass Spectrometry & NMR analysis), transgenics, physiology and pharmacology.
The BMSRI research infrastructure also includes centralized resources for: high throughput drug screening in vitro assays, clinical research & human intervention studies/ trials; the use and storage of mammalian cells and tissues; and in vivo studies in Animal reporter gene models and animal models that replicate human disease. The BMSRI uses its estate of equipment, specialist laboratories, infrastructure and internationally recognized biomedical expertise to offer clinical & translational services to Academic Researchers and Industrial Business partners. The BMSRI routinely engages in collaborative research with some of the world's leading pharmaceutical and biomedical companies and through the support of Ulster's Office of Innovation, the University has established a track record of success in the commercialization of its research outcomes.
The SAAD Centre for Pharmacy and Diabetes provides contemporary and state-of-the-art facilities to support our diabetes and metabolomics research activities, as well as facilities for mass spectrometric and NMR analysis. This building also provides infrastructural support for our newly launched pharmacy/pharmaceutical sciences courses and associated research activities. These include: the formulation and production of antimicrobials for pharmaceutical applications; health promotion in community pharmacies; and the discovery and development of novel therapeutics such as anti-cancer agents, luminescent and nanoparticle sensors, bioimaging, photo/sono-dynamic therapy, and polymeric and nanoparticle drug delivery systems.